Ranibizumab or Aflibercept Monotherapies in Treatment-Naive Eyes with Diabetic Macular Edema: A Head-to-Head Comparison in Real-Life Experience

Ranibizumab or Aflibercept Monotherapies in Treatment-Naive Eyes with Diabetic Macular Edema: A Head-to-Head Comparison in Real-Life Experience

Objectives:To compare the functional and anatomical outcomes of ranibizumab and aflibercept monotherapies given according to a pro re nata (PRN) protocol in treatment-naive eyes with diabetic macular edema (DME) in a real-life clinical setting.Materials and Methods:The medical charts of treatment-na...

Full description

Bibliographic Details
Main Authors:	Mahmut Kaya, Taylan Öztürk, Nilüfer Koçak, Betül Akbulut Yağcı, Ferdane Ataş, Süleyman Kaynak
Format:	Article
Language:	English
Published:	Galenos Yayinevi 2023-02-01
Series:	Türk Oftalmoloji Dergisi
Subjects:	aflibercept diabetic macular edema pro re nata protocol ranibizumab
Online Access:	http://www.oftalmoloji.org/archives/archive-detail/article-preview/ranibizumab-or-aflibercept-monotherapies-in-treatm/58682

Similar Items

Aflibercept monotherapy or bevacizumab first for diabetic macular edema
by: Avner Hostovsky, et al.
Published: (2024-01-01)

Efficacy of Aflibercept versus Ranibizumab in the treatment of diabetic macular edema
by: Xiu-Xian Wang, et al.
Published: (2021-12-01)

Comparative study between ranibizumab and aflibercept in the management of macular edema caused by diabetes mellitus in age group more than 40 years
by: Abd El-Magid M Tag El-Din
Published: (2019-01-01)

Efficacy of intravitreal injection of Aflibercept vs Ranibizumab in the treatment of diabetic retinopathy
by: Chang Huang, et al.
Published: (2021-05-01)

The Impact of Interval between Recurrence and Reinjection in Anti-VEGF Therapy for Diabetic Macular Edema in Pro Re Nata Regimen
by: Yoshihiro Takamura, et al.
Published: (2021-12-01)

Efficacy of Aflibercept and Ranibizumab in the treatment of diabetic macular edema
by: Bing Wu, et al.
Published: (2023-08-01)

Ranibizumab versus Aflibercept in Macular Edema Secondary to Retinal Vein Occlusion in Real Life: A Retrospective Case Control Study
by: Abdullah Özkaya, et al.
Published: (2017-05-01)

Results of switchback from ranibizumab to aflibercept in patients with exudative age-related macular degeneration
by: Koike N, et al.
Published: (2019-07-01)

Faricimab for Diabetic Macular Edema in Patients Refractory to Ranibizumab or Aflibercept
by: Hiromi Ohara, et al.
Published: (2023-06-01)

Comparison between the Effect of Aflibercept (Eylea) and Ranibizumab (Lucentis) on Intraocular Pressure after 3rd Injection in Treatment of Diabetic Macular Edema
by: Hossam El Deen Khalil, et al.
Published: (2022-07-01)

Intravitreal Aflibercept Therapy in Intravitreal Bevacizumab/Ranibizumab Treatment-resistant Exudative Age-related Macular Degeneration
by: Neslihan Sevimli, et al.
Published: (2023-09-01)

Short-Term Outcomes of Switching to Ranibizumab in Polypoidal Choroidal Vasculopathy Resistant to Aflibercept Therapy
by: Young-Joon Jeon, et al.
Published: (2021-12-01)

Ranibizumab versus aflibercept for macular edema secondary to nonischemic central retinal vein occlusion in young adult patients
by: Ahmed A Amer, et al.
Published: (2022-01-01)

A Real-Life Study: Intravitreal Aflibercept, Ranibizumab and Dexamethasone for Macular Edema Secondary to Branch Retinal Vein Occlusion
by: Alper Halil Bayat, et al.
Published: (2019-12-01)

Comparison of 2-Year Outcomes between Intravitreal Ranibizumab and Intravitreal Aflibercept for Diabetic Macular Edema with “Treat-and-Extend” Regimen—Its Usefulness and Problems
by: Shinichiro Chujo, et al.
Published: (2020-09-01)

Aflibercept versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edema
by: Alsaedi NG, et al.
Published: (2021-07-01)

The efficacy and ocular safety following aflibercept, conbercept, ranibizumab, bevacizumab, and laser for retinopathy of prematurity: a systematic review and meta-analysis
by: Jing Chen, et al.
Published: (2023-10-01)

Transient Vision Loss Associated with Prefilled Aflibercept Syringes
by: Daniel J. Lee, MD, et al.
Published: (2022-06-01)

Effect of repeated intravitreal Ranibizumab and Aflibercept injections on the corneal nerves in patients with macular edema
by: Yuan-Yuan Qi, et al.
Published: (2023-05-01)

Comparison of Ranibizumab and Pegabtanib Sodium Monotherapies in Terms of Rates of Stabilization After the First Three Doses
by: Nilüfer Koçak, et al.
Published: (2012-05-01)

Comparison of Two-Year Outcome of Photodynamic Therapy in Combination with Intravitreal Aflibercept or Ranibizumab for Polypoidal Choroidal Vasculopathy
by: Hsin-Yu Weng, et al.
Published: (2021-01-01)

Effects of intravitreal injection of ranibizumab and aflibercept for branch retinal vein occlusion on the choroid: a retrospective study
by: Shuta Kishishita, et al.
Published: (2022-11-01)

Pharmacoeconomic analysis of ranibizumab and aflibercept for treatment of diabetic macular edema
by: A. E. Cheberda, et al.
Published: (2018-05-01)

Effects of Intravitreal Injection of Ranibizumab and Aflibercept on Corneal Endothelium and Central Corneal Thickness
by: Mehmet Coskun
Published: (2018-08-01)

Short-term outcomes in patients with branch retinal vein occlusion who received intravitreal aflibercept with or without intravitreal ranibizumab
by: Sakanishi Y, et al.
Published: (2017-05-01)

Real-World Results of Switching Treatment from Ranibizumab to Aflibercept in Macular Oedema Secondary to Branch Retinal Vein Occlusion
by: Vasileios E. Konidaris, et al.
Published: (2018-10-01)

Two Year Study of Aflibercept and Ranibizumab Intravitreal Therapy in Patients with Wet AMD
by: Dorota Luksa, et al.
Published: (2021-11-01)

Intravitreal aflibercept in neovascular age-related macular degeneration previously treated with ranibizumab
by: Rachel Hui Fen Lim, et al.
Published: (2017-03-01)

Evaluation of contrast sensitivity and other visual function outcomes in diabetic macular edema patients following treatment switch to aflibercept from ranibizumab
by: Nixon DR, et al.
Published: (2018-01-01)

Clinical outcomes of switching to aflibercept using a pro re nata treatment regimen in patients with neovascular age-related macular degeneration who incompletely responded to ranibizumab
by: Flora Elwes, et al.
Published: (2018-01-01)

Does HbA1c Level or Glomerular Filtration Rate Affect the Clinical Response to Endothelial Growth Factor Therapy (Ranibizumab or Aflibercept) in Diabetic Macular Edema? A Real-Life Experience
by: Eloi Debourdeau, et al.
Published: (2023-07-01)

Injections frequency and health care costs in patients treated with aflibercept compared to ranibizumab: new real-life evidence from Switzerland
by: Oliver Reich, et al.
Published: (2017-12-01)

Comparison of the effectiveness of various protocols for the transition to aflibercept with tachyphylaxis for ranibizumab in patients with neovascular AMD
by: A. N. Kulikov, et al.
Published: (2018-11-01)

Short-term results of early switch from Ranibizumab to Aflibercept in poor or non responder age related macular degeneration in clinical practice
by: Luciana de Sá Quirino-Makarczyk, et al.
Published: (2020-05-01)

Comparison of efficacy of conbercept, aflibercept, and ranibizumab ophthalmic injection in the treatment of macular edema caused by retinal vein occlusion: a Meta-analysis
by: Qiu Xing, et al.
Published: (2023-07-01)

Clinical therapeutic effects of Aflibercept or Ranibizumab combined with Ahmed glaucoma valve implantation on neovascular glaucoma
by: Peng-Yi Zhou, et al.
Published: (2022-06-01)

Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab
by: Daniel Sanju Narayan, et al.
Published: (2015-01-01)

Switching to Brolucizumab in Neovascular Age-Related Macular Degeneration Incompletely Responsive to Ranibizumab or Aflibercept: Real-Life 6 Month Outcomes
by: Christof Haensli, et al.
Published: (2021-06-01)

AFLIBERCEPT IN TREATMENT OF RESISTANT POLYPOID CHOROIDAL VASCULOPATHY: SHORT-TERM RESULTS
by: E. K. Pedanova, et al.
Published: (2017-12-01)

Peripapillary Choroidal Neovascular Membrane Secondary to Sarcoidosis-Related Panuveitis: Treatment with Aflibercept and Ranibizumab with a 50-month Follow-Up
by: Artemis Matsou, et al.
Published: (2021-04-01)